Castle Biosciences: Changing The Way Dermatologic Cancers Are Treated And Managed

Castle Biosciences: Changing the Way Dermatologic Cancers are Treated and Managed

Castle Biosciences

Castle Biosciences: The Skin Cancer Diagnostics Company

Castle Biosciences

Melanoma and the Role of Personalized Medicine: A Dermatologist/Dermatopathologist’s Perspective

Castle Biosciences

Castle Biosciences Tests for Skin Cancer: Dr. Dmitriy Timerman on the Benefits

Castle Biosciences

Molecular Prognostic Tests are Changing Management of Dermatologic Cancers

Castle Biosciences

Using Molecular Diagnostics to Inform Cancer Management Decisions / by Matthew Goldberg at PMWC 2023

Castle Biosciences

How DecisionDx-Melanoma works and data supporting it

Castle Biosciences

Why do Clinicians Supports Castle Biosciences' Impact on Cancer Care

Castle Biosciences

The DecisionDx®-Melanoma Test Complements Current Melanoma Staging

Castle Biosciences

DecisionDx®-Melanoma Helps to Guide Patient Management Decisions

Castle Biosciences

Cases with Castle Biosciences – Angela Wingfield, M.D

Castle Biosciences

Dr. Moody - Advances in Cutaneous Melanoma

Castle Biosciences

Cases with Castle Biosciences - Barry White, M.D.

Castle Biosciences

Precision Oncology: DecisionDx®-Melanoma and the Evolution of GEP Testing in Cutaneous Melanoma

Castle Biosciences

IMPACT Melanoma Webinar OnDemand

Castle Biosciences

DecisionDx®-Melanoma Provides the Future of Melanoma Prognosis for Patient, Today

Castle Biosciences

Is Gene Expression Profiling replacing staging in melanoma? Learn how GEP and staging work together

Castle Biosciences

AHNS DecisionDx–SCC Webinar: Identifying the Risk of Metastasis in cSCC and cSCC-HN Patients

Castle Biosciences

Dr. Sligh - Incorporating Prognostic Gene Expression Profiling in the Management of Skin Cancer

Castle Biosciences

DecisionDx®-Melanoma Increases the Risk Prediction that is Currently Available for Patients

Castle Biosciences